Status:
COMPLETED
Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery
Lead Sponsor:
Pfizer
Conditions:
Cardiac Surgery Subjects
Subjects Undergoing CABG and/or Cardiac Valve Replacement
Eligibility:
All Genders
48-82 years
Phase:
PHASE2
Brief Summary
This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replaceme...
Eligibility Criteria
Inclusion
- Has been identified for coronary artery bypass grafting (CABG), aortic and/or mitral valve replacement, or combined CABG and cardiac valve replacement procedures that require cardiopulmonary bypass (CPB).
Exclusion
- Requires an emergent or "emergency" CABG and/or cardiac valve replacement.
Key Trial Info
Start Date :
August 10 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2008
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00838383
Start Date
August 10 2006
End Date
March 31 2008
Last Update
September 8 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania,
Philadelphia, Pennsylvania, United States, 19104
2
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
3
The Chattanooga Heart Institute
Chattanooga, Tennessee, United States, 37404